AAN Official Guideline: Cannabis for MS Spasticity, Pain, and Urinary Symptoms
The American Academy of Neurology formally recommended oral cannabis extract for MS spasticity and pain (Level A), with Sativex recommended for spasticity symptoms, pain, and urinary frequency (Level B).
Quick Facts
What This Study Found
This is the full guideline publication (not the commentary). Key recommendations:
Level A (established): Clinicians might offer oral cannabis extract for spasticity symptoms and pain (excluding central neuropathic pain).
Level B (probable): THC for spasticity symptoms and pain; Sativex for spasticity symptoms, pain, and urinary frequency. These agents are probably ineffective for objective spasticity (short-term) and tremor. Sativex probably ineffective for objective spasticity and urinary incontinence.
Level C (possible): Cannabis agents possibly effective long-term for spasticity and pain.
The guidelines emphasize that cannabinoids may cause adverse effects and that clinicians should exercise caution regarding standardized versus non-standardized preparations and overall quality control.
Key Numbers
Literature searched: 1970-September 2013. Level A: oral cannabis extract for spasticity symptoms/pain. Level B: THC and Sativex for symptoms/pain; ineffective for objective measures. Safety/efficacy of CAM interaction with MS disease-modifying therapies: unknown.
How They Did This
Systematic literature review from 1970 to September 2013, with articles classified according to AAN evidence standards. Recommendations were graded based on evidence strength (Level A through Level C). The guideline development subcommittee included experts in MS, neurology, and evidence-based medicine.
Why This Research Matters
This is the definitive AAN guideline on complementary and alternative medicine in MS, setting the standard of care for cannabis-based treatments in neurology practice. Its systematic methodology and graded recommendations provide clear clinical guidance.
The Bigger Picture
These guidelines changed the conversation about cannabis in neurology from fringe therapy to evidence-based recommendation. The careful distinction between what cannabis can and cannot do for MS, supported by systematic evidence review, provides a model for how cannabis should be integrated into medical practice.
What This Study Doesn't Tell Us
The literature search ended in September 2013 and does not include subsequent studies. U.S. access to standardized cannabis preparations remains limited. The guidelines acknowledge unknown interactions between cannabis and MS disease-modifying therapies. The distinction between subjective and objective outcomes creates clinical ambiguity.
Questions This Raises
- ?How should these guidelines be applied in states where medical cannabis is legal but unregulated?
- ?Do newer studies change any of the recommendations?
- ?Should objective or subjective outcomes be prioritized in clinical decision-making?
Trust & Context
- Key Stat:
- Level A (highest evidence): oral cannabis extract for MS spasticity symptoms and pain
- Evidence Grade:
- This is the official systematic evidence-based guideline from the American Academy of Neurology, the highest tier of clinical evidence synthesis.
- Study Age:
- Published in 2014. These guidelines remain influential, though the evidence base has continued to grow.
- Original Title:
- Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.
- Published In:
- Neurology, 82(12), 1083-92 (2014)
- Authors:
- Yadav, Vijayshree(4), Bever, Christopher, Bowen, James, Bowling, Allen, Weinstock-Guttman, Bianca, Cameron, Michelle, Bourdette, Dennis, Gronseth, Gary S, Narayanaswami, Pushpa
- Database ID:
- RTHC-00897
Evidence Hierarchy
Analyzes all available research on a topic using a structured method.
What do these levels mean? →Frequently Asked Questions
What is the difference between Level A, B, and C recommendations?
Level A (established): strong evidence of effectiveness. Level B (probable): probable evidence. Level C (possible): possible evidence. Each level reflects the quality and consistency of the underlying research.
Can I use dispensary cannabis based on these guidelines?
The guidelines specifically note concerns about non-standardized cannabis preparations and lack of quality control. They recommend standardized, pharmaceutical-grade preparations where available. Dispensary products may vary significantly in composition and potency.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00897APA
Yadav, Vijayshree; Bever, Christopher; Bowen, James; Bowling, Allen; Weinstock-Guttman, Bianca; Cameron, Michelle; Bourdette, Dennis; Gronseth, Gary S; Narayanaswami, Pushpa. (2014). Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.. Neurology, 82(12), 1083-92. https://doi.org/10.1212/WNL.0000000000000250
MLA
Yadav, Vijayshree, et al. "Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.." Neurology, 2014. https://doi.org/10.1212/WNL.0000000000000250
RethinkTHC
RethinkTHC Research Database. "Summary of evidence-based guideline: complementary and alter..." RTHC-00897. Retrieved from https://rethinkthc.com/research/yadav-2014-summary-of-evidencebased-guideline
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.